<DOC>
	<DOCNO>NCT02146547</DOCNO>
	<brief_summary>Schizophrenia chronic psychiatric illness period remission relapse . Patients vary frequency severity relapse , time relapse time remission . Discontinuation antipsychotic medication far important reason relapse . A possible method optimize medication adherence treat patient long-term , depot medication rather oral medication . However , despite apparent `` common sense '' approach neither universally accept practice psychiatrist unequivocally demonstrate clinical trial . Therefore , study aim investigate possible advantage depot medication oral antipsychotic independently design conduct , randomize , pragmatic trial .</brief_summary>
	<brief_title>European Long-acting Antipsychotics Schizophrenia Trial</brief_title>
	<detailed_description>It remain unclear depot medication reduce relapse rate improve clinical outcome offer patient need continuation treatment antipsychotic . Before conclude whether schizophrenia patient could benefit switch depot formulation , several question remain answered . Is depot medication associate good continuation rate outcome ? How depot medication tolerate compare oral medication ? In order clarify important issue aim perform large multi-center trial schizophrenia patient need continuous treatment randomize 1:1:1:1 two different depot preparation two different oral medication . In pragmatic , randomize , open label , multicenter , multinational comparative trial , schizophrenic patient age 18 year old , experience first psychosis 1-7 year ago , indication ( patient physician initiate ) receive medication switch another antipsychotic drug , enter study . The study duration one month medication switch follow-up 18 month . Patients refuse take part study ask give consent participate naturalistic follow-up , follow Clinical Global Impression list ( CGI ) closely related study schedule possible , unless also refuse .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>1 . Diagnosis schizophrenia define DSMIVR ( Diagnostic Statistical Manual ) determine M.I.N.I.plus 2 . Age 18 old . 3 . The first psychosis occur least one year 7 year ago . 4 . If patient use antipsychotic drug , medication switch currently consideration . 5 . Capable provide write informed consent 1 . Intolerance / hypersensitivity one drug ( include active substance , metabolites excipients ) study include oral paliperidone aripiprazole and/or hypersensitivity risperidone . 2 . Pregnancy lactation . 3 . Patients currently use clozapine . 4 . Patients fully comprehend purpose competent make rational decision whether participate . 5 . Patients document history intolerance study medication and/or documented history nonresponse treatment one study drug least 6 week within register dose range . 6 . Forensic patient . 7 . Patients treat investigational drug within 30 day prior screen . 8 . Simultaneous participation another intervention study ( neither medication psychosocial intervention ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>depot , oral , antipsychotic , paliperidone , aripiprazole</keyword>
</DOC>